Cargando…

Drug resistance reversed by silencing LIM domain-containing protein 1 expression in colorectal carcinoma

The role of LIM domain-containing protein 1 (LIMD1) in the multidrug resistance of colorectal carcinoma (CRC) has not yet been established. The aim of the current study was to investigate the chemosensitivity of CRC multidrug-resistant (MDR) cells following the silencing of LIMD1. The MDR phenotypic...

Descripción completa

Detalles Bibliográficos
Autores principales: CHEN, ZHANGXING, ZHU, XIAOSAN, XIE, TAO, XIE, JUNPEI, QUO, KONG, LIU, XIANG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081406/
https://www.ncbi.nlm.nih.gov/pubmed/25013501
http://dx.doi.org/10.3892/ol.2014.2155
_version_ 1782324103023165440
author CHEN, ZHANGXING
ZHU, XIAOSAN
XIE, TAO
XIE, JUNPEI
QUO, KONG
LIU, XIANG
author_facet CHEN, ZHANGXING
ZHU, XIAOSAN
XIE, TAO
XIE, JUNPEI
QUO, KONG
LIU, XIANG
author_sort CHEN, ZHANGXING
collection PubMed
description The role of LIM domain-containing protein 1 (LIMD1) in the multidrug resistance of colorectal carcinoma (CRC) has not yet been established. The aim of the current study was to investigate the chemosensitivity of CRC multidrug-resistant (MDR) cells following the silencing of LIMD1. The MDR phenotypic Colo205 and HCT-8 cell lines were examined, which were established by exposure to increasing doses of 5-fluorouracil (5-FU) over a period of one year. LIMD1 siRNA constructs were transfected into CRC MDR cells and the phenotypic effects were determined comprehensively. The Colo205 and HCT-8 cell lines were more resistant to 5-FU compared with their respective parental cell lines. In addition, the two MDR cell types expressed significantly more LIMD1 compared with their parental lines. The stably transfected cells showed various degrees of reversal of the MDR phenotype, and 5-FU-induced apoptosis was increased in the transfected cells compared with the controls. In conclusion, RNA interference targeting LIMD1 may present a novel therapeutic option for CRC.
format Online
Article
Text
id pubmed-4081406
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-40814062014-07-10 Drug resistance reversed by silencing LIM domain-containing protein 1 expression in colorectal carcinoma CHEN, ZHANGXING ZHU, XIAOSAN XIE, TAO XIE, JUNPEI QUO, KONG LIU, XIANG Oncol Lett Articles The role of LIM domain-containing protein 1 (LIMD1) in the multidrug resistance of colorectal carcinoma (CRC) has not yet been established. The aim of the current study was to investigate the chemosensitivity of CRC multidrug-resistant (MDR) cells following the silencing of LIMD1. The MDR phenotypic Colo205 and HCT-8 cell lines were examined, which were established by exposure to increasing doses of 5-fluorouracil (5-FU) over a period of one year. LIMD1 siRNA constructs were transfected into CRC MDR cells and the phenotypic effects were determined comprehensively. The Colo205 and HCT-8 cell lines were more resistant to 5-FU compared with their respective parental cell lines. In addition, the two MDR cell types expressed significantly more LIMD1 compared with their parental lines. The stably transfected cells showed various degrees of reversal of the MDR phenotype, and 5-FU-induced apoptosis was increased in the transfected cells compared with the controls. In conclusion, RNA interference targeting LIMD1 may present a novel therapeutic option for CRC. D.A. Spandidos 2014-08 2014-05-19 /pmc/articles/PMC4081406/ /pubmed/25013501 http://dx.doi.org/10.3892/ol.2014.2155 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
CHEN, ZHANGXING
ZHU, XIAOSAN
XIE, TAO
XIE, JUNPEI
QUO, KONG
LIU, XIANG
Drug resistance reversed by silencing LIM domain-containing protein 1 expression in colorectal carcinoma
title Drug resistance reversed by silencing LIM domain-containing protein 1 expression in colorectal carcinoma
title_full Drug resistance reversed by silencing LIM domain-containing protein 1 expression in colorectal carcinoma
title_fullStr Drug resistance reversed by silencing LIM domain-containing protein 1 expression in colorectal carcinoma
title_full_unstemmed Drug resistance reversed by silencing LIM domain-containing protein 1 expression in colorectal carcinoma
title_short Drug resistance reversed by silencing LIM domain-containing protein 1 expression in colorectal carcinoma
title_sort drug resistance reversed by silencing lim domain-containing protein 1 expression in colorectal carcinoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081406/
https://www.ncbi.nlm.nih.gov/pubmed/25013501
http://dx.doi.org/10.3892/ol.2014.2155
work_keys_str_mv AT chenzhangxing drugresistancereversedbysilencinglimdomaincontainingprotein1expressionincolorectalcarcinoma
AT zhuxiaosan drugresistancereversedbysilencinglimdomaincontainingprotein1expressionincolorectalcarcinoma
AT xietao drugresistancereversedbysilencinglimdomaincontainingprotein1expressionincolorectalcarcinoma
AT xiejunpei drugresistancereversedbysilencinglimdomaincontainingprotein1expressionincolorectalcarcinoma
AT quokong drugresistancereversedbysilencinglimdomaincontainingprotein1expressionincolorectalcarcinoma
AT liuxiang drugresistancereversedbysilencinglimdomaincontainingprotein1expressionincolorectalcarcinoma